01:33 PM EDT, 03/22/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended market authorization for Emblaveo to treat complex infections.

Recommended treatment guidelines cover adult patients with complicated intra-abdominal infections, hospital-acquired pneumonia, including ventilator-associated pneumonia, and complicated urinary tract infections, according to the company.

The recommendation is based on results from Pfizer's ( PFE ) phase 3 program showing Emblaveo's effectiveness and tolerance, and a similar safety profile to aztreonam, the company added.

Pfizer ( PFE ) said the European Commission will now review CHMP's recommendation and a final decision is expected in coming months.

Price: 27.43, Change: -0.24, Percent Change: -0.85